等待开盘 04-03 09:30:00 美东时间
+0.030
+0.88%
Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed
03-26 04:17
Lifeward Ltd. announced the closure of its strategic partnership with Oramed Pharmaceuticals Inc., acquiring Oramed's POD™ technology and securing up to $47 million in capital, with $10 million accessed. The partnership aims to diversify Lifeward's biomedical portfolio and enhance profitability, supporting its mission to innovate for individuals with physical limitations.
03-25 20:10
Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its
03-13 20:03
Lifeward Ltd. shareholders approved a strategic partnership with Oramed Pharmaceuticals Inc., integrating Oramed’s POD™ oral delivery technology and accessing up to $47 million in capital. The partnership aims to strengthen Lifeward’s path to profitability while expanding into biotech markets. Lifeward will focus on three core priorities: driving profitability from its MedTech portfolio, selectively investing in innovative technologies, and build...
03-13 12:00
The latest announcement is out from Oramed Pharm ( ($ORMP) ). On February 19, 2...
02-21 05:53
Pharmaceutical (PJP), (XPH), (PPH) and biotechnology stocks (XBI), (BBH) have officially returned to favor on Wall Street, according to Michael Yee, global head of biotechnology equity research at UBS...
02-14 03:01
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder
01-13 21:18
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward ...
01-13 20:58
Lifeward Ltd has secured up to $47 million in strategic investment from Oramed Pharmaceuticals and another investor to drive profitability and diversify its portfolio into biotech. Lifeward acquired Oramed's Protein Oral Delivery (POD™) technology, targeting the $600+ billion injectable drugs market, including the potential first oral insulin medicine, ORMD-0801. The transaction allows Lifeward to focus on existing MedTech products like ReWalk an...
01-13 13:00
Oramed Pharm ( ($ORMP) ) has provided an update. On January 7, 2026, Oramed Pha...
01-07 22:17